Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Onco-Innovations Ltd. ( (TSE:ONCO) ) just unveiled an announcement.
Onco-Innovations Ltd. announced promising results from a study demonstrating that its PNKP inhibitor technology significantly increases the sensitivity of PTEN-deficient cancer cells to radiation, potentially paving the way for more effective and less toxic cancer treatments. The study suggests that this technology could allow for lower radiation doses, minimizing harm to healthy tissue and improving patient outcomes, thereby enhancing Onco-Innovations’ position as a leader in oncology.
More about Onco-Innovations Ltd.
Onco-Innovations Ltd. operates in the biotechnology industry, focusing on developing advanced cancer treatment technologies. The company specializes in Polynucleotide Kinase 3′-Phosphatase (PNKP) inhibitors, aimed at enhancing the effectiveness of cancer therapies, with a particular emphasis on targeted treatments for better patient outcomes.
YTD Price Performance: 151.76%
Average Trading Volume: 394,846
For detailed information about ONCO stock, go to TipRanks’ Stock Analysis page.
